Following the World Health Organization (WHO) publication of research from a clinical trial showing that remdesivir barely reduces the mortality rate of COVID-19 patients, member of the Georgetown Public Hospital’s Task Force for COVID-19 Dr Mahendra Carpen has said that there are no immediately plans to discontinue using it to treat patients here as it seems to be reducing the amount of time those with symptoms remain hospitalised.
The non-peer-reviewed preprint WHO study found that interim results from the Solidarity Therapeutics Trial indicates that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.
The study looked at the effects of those treatments on overall mortality, initiation of ventilation, and duration of hospital stay in hospitalised patients. The study lasted for a period of six months.
